Derwahl, Karl-Michael
3 papers on CoChat
Most cited papers
- Verified
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 3,163
- Verified
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 638
- Verified
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International
Chronic Kidney Disease and DiabetesDiabetes Treatment and Management
Cited by 49
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free